Moisés Mercado
Endocrinology, Volume 165, Issue 10, October 2024, bqae108
https://doi.org/10.1210/endocr/bqae108
The diagnosis and treatment of Cushing disease (CD) is perhaps one of the most challenging endeavors of clinical endocrinology. Currently available medications to treat recurrent or persistent CD are frequently limited by side effects and do not always target the origin of the disease. More recently, as the molecular oncogenesis of corticotroph tumors begins to be unveiled, several targeted therapies for CD have emerged. Although to varying degrees all these new medications inhibit POMC gene transcription and ACTH secretion as well as cellular proliferation and promote apoptosis, both in the murine corticotroph tumor cell line AtT-20 and in animal models of CD, none of them are readily available for clinical use. It is in this context that new compounds are being designed and repurposed using sophisticated techniques and high-throughput methodologies, such as molecular docking, to eventually be able to offer these patients a therapeutic alternative. This commentary describes a recent article published in Endocrinology by Hakata and colleagues from Kyoto University.
We provide our journal authors with a variety of resources for increasing the discoverability and citation of their published work. Use these tools and tips to broaden the impact of your article.
Read our special collections of Endocrine Society journal articles, curated by topic, Altmetric Attention Scores, and Featured Article designations.
